Whole-genome landscape of adult T-cell leukemia/lymphoma.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
17 02 2022
Historique:
received: 05 08 2021
accepted: 11 10 2021
pubmed: 26 10 2021
medline: 1 3 2022
entrez: 25 10 2021
Statut: ppublish

Résumé

Adult T-cell leukemia/lymphoma (ATL) is an aggressive neoplasm immunophenotypically resembling regulatory T cells, associated with human T-cell leukemia virus type-1. Here, we performed whole-genome sequencing (WGS) of 150 ATL cases to reveal the overarching landscape of genetic alterations in ATL. We discovered frequent (33%) loss-of-function alterations preferentially targeting the CIC long isoform, which were overlooked by previous exome-centric studies of various cancer types. Long but not short isoform-specific inactivation of Cic selectively increased CD4+CD25+Foxp3+ T cells in vivo. We also found recurrent (13%) 3'-truncations of REL, which induce transcriptional upregulation and generate gain-of-function proteins. More importantly, REL truncations are also common in diffuse large B-cell lymphoma, especially in germinal center B-cell-like subtype (12%). In the non-coding genome, we identified recurrent mutations in regulatory elements, particularly splice sites, of several driver genes. In addition, we characterized the different mutational processes operative in clustered hypermutation sites within and outside immunoglobulin/T-cell receptor genes and identified the mutational enrichment at the binding sites of host and viral transcription factors, suggesting their activities in ATL. By combining the analyses for coding and noncoding mutations, structural variations, and copy number alterations, we discovered 56 recurrently altered driver genes, including 11 novel ones. Finally, ATL cases were classified into 2 molecular groups with distinct clinical and genetic characteristics based on the driver alteration profile. Our findings not only help to improve diagnostic and therapeutic strategies in ATL, but also provide insights into T-cell biology and have implications for genome-wide cancer driver discovery.

Identifiants

pubmed: 34695199
pii: S0006-4971(21)01784-5
doi: 10.1182/blood.2021013568
pmc: PMC8854674
doi:

Substances chimiques

ATXN1 protein, human 0
Ataxin-1 0
Biomarkers, Tumor 0
CIC protein, human 0
Proto-Oncogene Proteins c-rel 0
REL protein, human 0
Repressor Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

967-982

Subventions

Organisme : NCI NIH HHS
ID : R01 CA223232
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022 by The American Society of Hematology.

Références

Blood. 2018 Oct 4;132(14):1507-1518
pubmed: 30104217
Nat Genet. 2017 Jan;49(1):87-96
pubmed: 27869830
Nat Genet. 2020 Mar;52(3):306-319
pubmed: 32024998
J Clin Oncol. 2019 Mar 10;37(8):677-687
pubmed: 30657736
Cell. 2002 Sep 20;110(6):673-87
pubmed: 12297042
Science. 2018 Nov 9;362(6415):694-699
pubmed: 30409884
J Clin Oncol. 2009 Jan 20;27(3):453-9
pubmed: 19064971
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Nat Commun. 2020 Feb 5;11(1):734
pubmed: 32024818
Blood. 2003 May 1;101(9):3681-6
pubmed: 12511414
Lancet Oncol. 2014 Oct;15(11):e517-26
pubmed: 25281470
Cancer Discov. 2018 Dec;8(12):1614-1631
pubmed: 30266814
Cell. 2018 Jul 26;174(3):758-769.e9
pubmed: 30033370
Cell Death Dis. 2021 Apr 28;12(5):419
pubmed: 33911074
Cancer Cell. 2018 Aug 13;34(2):286-297.e10
pubmed: 30057145
Blood. 2020 Apr 23;135(17):1467-1471
pubmed: 31961925
Nat Commun. 2017 Jul 12;8:16037
pubmed: 28855737
Genes Cancer. 2011 Jul;2(7):695-711
pubmed: 22207895
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Nature. 2014 Jan 23;505(7484):495-501
pubmed: 24390350
Trends Genet. 2020 Dec;36(12):936-950
pubmed: 32873422
Blood. 2018 Oct 18;132(16):1695-1702
pubmed: 30126979
Nat Rev Cancer. 2007 Apr;7(4):270-80
pubmed: 17384582
Nature. 2020 Feb;578(7793):82-93
pubmed: 32025007
Nat Commun. 2018 Oct 1;9(1):4001
pubmed: 30275490
Blood. 2020 Jun 4;135(23):2023-2032
pubmed: 32160278
Nature. 2020 Feb;578(7793):94-101
pubmed: 32025018
Leukemia. 2015 May;29(5):1177-85
pubmed: 25428260
Science. 2013 Oct 04;342(6154):1235587
pubmed: 24092746
Nature. 2009 Jun 4;459(7247):717-21
pubmed: 19412164
Nature. 2020 Feb;578(7793):102-111
pubmed: 32025015
Oncogene. 1991 Jul;6(7):1235-41
pubmed: 1650444
Nat Commun. 2015 Dec 07;6:8866
pubmed: 26638776
Nucleic Acids Res. 2015 Sep 30;43(17):8123-34
pubmed: 26304545
J Cell Sci. 2012 Mar 15;125(Pt 6):1383-91
pubmed: 22526417
Nature. 2016 Apr 14;532(7598):264-7
pubmed: 27075101
Nat Genet. 2015 Nov;47(11):1304-15
pubmed: 26437031
Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21426-31
pubmed: 23213202
Neuron. 2018 Mar 21;97(6):1235-1243.e5
pubmed: 29526553
Am J Hematol. 2016 Sep;91(9):923-30
pubmed: 27312795
Nature. 2015 Oct 22;526(7574):519-24
pubmed: 26200345
Nature. 2016 May 23;534(7607):402-6
pubmed: 27281199
Cell. 2006 Dec 29;127(7):1335-47
pubmed: 17190598
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
Leukemia. 2019 Dec;33(12):2867-2883
pubmed: 31092896
Cell. 2017 Nov 16;171(5):1029-1041.e21
pubmed: 29056346
Nat Rev Immunol. 2013 Apr;13(4):257-69
pubmed: 23524462

Auteurs

Yasunori Kogure (Y)

Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.

Takuro Kameda (T)

Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Junji Koya (J)

Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.

Makoto Yoshimitsu (M)

Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.

Kisato Nosaka (K)

Department of Hematology, Rheumatology, and Infectious Disease, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Jun-Ichirou Yasunaga (JI)

Department of Hematology, Rheumatology, and Infectious Disease, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Yoshitaka Imaizumi (Y)

Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.

Mizuki Watanabe (M)

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Yuki Saito (Y)

Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Department of Gastroenterology, Keio University School of Medicine, Tokyo, Japan.

Yuta Ito (Y)

Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.

Marni B McClure (MB)

Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.

Mariko Tabata (M)

Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Sumito Shingaki (S)

Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.

Kota Yoshifuji (K)

Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Department of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Kenichi Chiba (K)

Division of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.

Ai Okada (A)

Division of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.

Nobuyuki Kakiuchi (N)

Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Yasuhito Nannya (Y)

Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Ayako Kamiunten (A)

Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Yuki Tahira (Y)

Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Keiichi Akizuki (K)

Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Masaaki Sekine (M)

Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Kotaro Shide (K)

Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Tomonori Hidaka (T)

Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Yoko Kubuki (Y)

Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Akira Kitanaka (A)

Department of Laboratory Medicine, Kawasaki Medical School, Kurashiki, Japan.

Michihiro Hidaka (M)

Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.

Nobuaki Nakano (N)

Department of Hematology, Imamura General Hospital, Kagoshima, Japan.

Atae Utsunomiya (A)

Department of Hematology, Imamura General Hospital, Kagoshima, Japan.

R Alejandro Sica (RA)

Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.

Ana Acuna-Villaorduna (A)

Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.

Murali Janakiram (M)

Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.

Urvi Shah (U)

Department of Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.

Juan Carlos Ramos (JC)

Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL.

Tatsuhiro Shibata (T)

Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.
Laboratory of Molecular Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Kengo Takeuchi (K)

Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.

Akifumi Takaori-Kondo (A)

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Yasushi Miyazaki (Y)

Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.

Masao Matsuoka (M)

Department of Hematology, Rheumatology, and Infectious Disease, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Kenji Ishitsuka (K)

Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.

Yuichi Shiraishi (Y)

Division of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.

Satoru Miyano (S)

M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan.

Seishi Ogawa (S)

Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

B Hilda Ye (BH)

Department of Cell Biology, Albert Einstein College of Medicine, New York, NY; and.

Kazuya Shimoda (K)

Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Keisuke Kataoka (K)

Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH